Dendreon (DNDN) Higher Ahead of Details of PROVENGE IMPACT Study
Tweet
Share
E-mail
Get Alerts DNDN Hot Sheet
Join SI Premium – FREE
Dendreon Corp (NASDAQ: DNDN) is up another 7.5% ahead of the American Urological Association Annual meeting tomorrow, which will have more details on the important PROVENGE IMPACT study. Dendreon is up 196% since reporting on April 14th that the drug was effective in improving overall survival compared to placebo in men with advanced prostate cancer.
Detailed results from the IMPACT study will be presented during a plenary session at the American Urological Association's Annual Meeting in Chicago on Tues., Apr. 28 at 2:20 pm CT.
Detailed results from the IMPACT study will be presented during a plenary session at the American Urological Association's Annual Meeting in Chicago on Tues., Apr. 28 at 2:20 pm CT.
You May Also Be Interested In
Create E-mail Alert Related Categories
FDA, Insiders' Blog, Momentum Movers, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
